Multiple endogenous growth factors and native bone extracellular matrix components (DBM components)

This term refers to the complex biological mixture found in demineralized bone matrix (DBM) and other bone allograft products used in orthopedic and regenerative medicine. It is not a single molecular target but rather a therapeutic composition consisting of structural proteins like Type I collagen and signaling molecules such as Bone Morphogenetic Proteins (BMPs), Transforming Growth Factor-beta (TGF-beta), and Insulin-like Growth Factors (IGFs). These components work in concert to facilitate bone repair through osteoconduction, where the matrix serves as a physical scaffold, and osteoinduction, where growth factors stimulate the differentiation of progenitor cells into osteoblasts. Clinically, these materials are employed to promote healing in non-union fractures, spinal fusions, and dental reconstructions. The therapeutic value of this mixture lies in its ability to mimic the natural microenvironment of bone tissue to accelerate the body's endogenous regenerative processes. Because it is derived from processed human or animal tissue, its efficacy is highly dependent on the preservation of these native proteins during sterilization and demineralization.

Other names

Demineralized Bone MatrixDBMBone AllograftOsteoinductive proteinsBone matrix proteins

These components provide a three-dimensional osteoconductive scaffold for cell attachment while simultaneously delivering osteoinductive growth factors that recruit and differentiate mesenchymal stem cells into bone-forming osteoblasts.